Scholar Rock price target raised to $60 from $53 at Raymond James

Raymond James analyst Martin Auster raised the firm’s price target on Scholar Rock (SRRK) to $60 from $53 and keeps a Strong Buy rating on the shares. Scholar Rock announced the resubmission of its BLA for apitegromab in spinal muscular atrophy following FDA alignment after a Type C meeting, including both the Catalent Indiana and a secondary U.S. fill-finish facility to strengthen supply, the analyst tells investors in a research note. If approved, apitegromab could see strong uptake as a differentiated muscle-targeted adjunct to SMN-modifying therapies, the firm says.